• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Archives of the Balkan Medical Union : >Evolution of immunobiological changes and their significance for the treatment of patients with Non-Hodgkin’s lymphoma
【24h】

Evolution of immunobiological changes and their significance for the treatment of patients with Non-Hodgkin’s lymphoma

机译：免疫生物学变化的演变及其对非霍奇金淋巴瘤患者的治疗意义

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction . Non-Hodgkin’s lymphoma (NHL) shows clonal and uncontrolled proliferation of immature lymphoid precursors. The aim of the study. Dynamic analysis of immunobiological and immunophenotypic parameters in the treatment of patients with NHL, and recognition of immunological remissions. Material and methods . The retrospective study group consisted of 122 patients, admitted between 2012 and 2015 in the Hematology Clinic of the Republic of Moldova Oncology Institute, with a morphologically confirmed diagnosis of NHL. We assessed the predominant phenotypic line by indirect immunophenotyping and total concentration of immunoglobulin classes (A, M, G) according to treatment regimens applied to NHL patients. Results. 119 patients showed CD19 antigen and CD20 increased expression of cell line B phenotype (84.4%); only 3 patients in the study showed increased CD3, CD5, resulting in the predominant T-cell phenotype line. NHL patients with both aggressive and non-aggressive primary variants after 3 cycles and 6 cycles presented a significant decrease in immunoglobulin A, M, and G indices, on average of 7.3±0.2(mg/ml) (p?0.05), while the immunological indices of patients treated with the polychemotherapy (PTCH) scheme 2 reported statistically significant minimal decreases (p 0.05), setting an incomplete immunological remission. Conclusions . Due to the information obtained by periodic monitoring of patients with NHL following the termination of conventional clinical protocols, it was possible to reveal the immunological and immunophenotypic features of the disease, for the detection of early and late recurrences, late side effects, occurrence of the second malignancy, with the evaluation of the immunological and immunophenotypic remission and identification of specific molecular targets for subsequent targeted therapy.
机译：介绍 。非霍奇金淋巴瘤（NHL）显示未成熟淋巴样前体的克隆性增殖和不受控制的增殖。研究的目的。免疫生物学和免疫表型参数在NHL患者治疗中的动态分析以及免疫缓解的识别。材料与方法 。回顾性研究组由122例患者组成，这些患者于2012年至2015年之间在摩尔多瓦共和国肿瘤研究所的血液学诊所接受了形态学确认的NHL诊断。我们根据适用于NHL患者的治疗方案，通过间接免疫表型分析和免疫球蛋白类别（A，M，G）的总浓度评估了主要的表型系。结果。 119例患者显示CD19抗原和CD20增加了细胞系B表型的表达（84.4％）;该研究中只有3例患者显示CD3，CD5升高，从而导致T细胞表型为主。在3个周期和6个周期后具有侵略性和非侵略性主要变体的NHL患者，其免疫球蛋白A，M和G指数均显着降低，平均7.3±0.2（mg / ml）（p？0.05），而接受多化学疗法（PTCH）方案2治疗的患者的免疫学指标报告有统计学上的显着最小降低（p <0.05），从而设置了不完全的免疫学缓解。结论。由于常规临床方案终止后通过定期监测NHL患者获得的信息，有可能揭示该疾病的免疫学和免疫表型特征，以检测早期和晚期复发，晚期副作用，第二种是恶性肿瘤，评估免疫和免疫表型缓解情况，并确定用于后续靶向治疗的特定分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号